Michael Cloonan
2020
In 2020, Michael Cloonan earned a total compensation of $4.6M as Chief Operating Officer at Sage Therapeutics, a 7% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $316,250 |
|---|---|
| Option Awards | $2,538,372 |
| Salary | $495,018 |
| Stock Awards | $1,269,463 |
| Other | $9,156 |
| Total | $4,628,259 |
Cloonan received $2.5M in option awards, accounting for 55% of the total pay in 2020.
Cloonan also received $316.3K in non-equity incentive plan, $495K in salary, $1.3M in stock awards and $9.2K in other compensation.
Rankings
In 2020, Michael Cloonan's compensation ranked 2,421st out of 13,090 executives tracked by ExecPay. In other words, Cloonan earned more than 81.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,421 out of 13,090 | 82nd |
Division Manufacturing | 926 out of 5,621 | 84th |
Major group Chemicals And Allied Products | 328 out of 2,254 | 85th |
Industry group Drugs | 279 out of 1,954 | 86th |
Industry Pharmaceutical Preparations | 201 out of 1,459 | 86th |
Source: SEC filing on April 29, 2021.
Cloonan's colleagues
We found five more compensation records of executives who worked with Michael Cloonan at Sage Therapeutics in 2020.